Amy A Eapen, MD

Biographical Statement

Dr. Amy Eapen is a board-certified allergist-immunologist and clinical researcher. She completed a pediatric residency at Riley Children’s Hospital and then a fellowship in Allergy and Immunology at Cincinnati Children’s Hospital. Her clinical interests include pediatric atopic dermatitis/eczema, food allergy, eosinophilic esophagitis and asthma. She is also the Director for the Henry Ford Health Center for Eczema and Food Allergy, a center focused on providing tertiary care to children and adults with atopic dermatitis and food allergy. This center is unique in its multiple multi-disciplinary clinics including partnerships with Dermatology (Eczema clinic) and Gastroenterology (EoE clinic).

Care Philosophy

I believe that medical care is a partnership between the patient and the provider. I am honored to be entrusted in my patient’s care, and in so, I try to find a plan that works for both their health conditions and the specific patient’s desires. Not every plan will work for every patient, and I think it is important to consider what the patient wants when deciding a treatment plan of action. I am also available to my patients when they need me, and try to advocate for them in all realms of their lives.

Research Interests

As a part of her allergy and immunology fellowship at Cincinnati Children’s Hospital, Dr. Eapen completed a NIH T32 fellowship where she investigated epigenetic modifications in children and adults with and without atopic dermatitis. She also completed a Master’s in Clinical and Translational Research as part of this training.

Her research program focused on identifying early-life DNA methylation patterns at birth in children who subsequently have atopic dermatitis and food allergy. She is a co-PI on the HFH site Environmental Children’s Health Outcomes (ECHO) study, and also an investigator in multiple other birth cohorts investigating atopic dermatitis, food allergy and asthma. She is dedicated to identifying early life biomarkers that are associated with later atopic disease and can be used as a newborn screen to risk stratify patients at birth who have subsequent atopic dermatitis and/or food allergy.